Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The disease has similar prevalence across high-income and low- and middle-income nations.
All-cause mortality rates were highest among those with NAFLD-related cirrhosis.
Developing treatments for fatty liver disease has proved challenging, and there are currently no approved medications.
As with HIV-negative individuals, non-alcoholic fatty liver disease is tied to diabetes and irregular blood lipids in those with HIV.
Hypertension raises the risk of heart disease and severe COVID-19.
Obesity increased the risk of liver disease to a smaller extent, according to a meta-analysis study.
Non-alcoholic fatty liver disease is more common among those with the virus compared with the general population.
Researchers argue that the distinctions between the two conditions are quite blurred.
And can treating the virus reduce the risk of chronic kidney and cardiovascular diseases as well as the risk of death from such causes?
This finding calls into question the importance of the one differentiation between alcoholic and non-alcoholic fatty liver disease.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.